GSK

1,921

+2.64%↑

PETS

186.7

+1.25%↑

GSK

1,921

+2.64%↑

PETS

186.7

+1.25%↑

GSK

1,921

+2.64%↑

PETS

186.7

+1.25%↑

GSK

1,921

+2.64%↑

PETS

186.7

+1.25%↑

GSK

1,921

+2.64%↑

PETS

186.7

+1.25%↑

Strona główna・Stock List・AstraZeneca PLC
Search

AstraZeneca PLC

Open

SectorHealthcare

13,762 3.49

Strong Buy

Price update 5 cze 2026, 09:23 UTC

BuySell

Overview

Share price change

24h

Current

Min

13246

Max

13782

Key metrics

By Trading Economics

Income

1.6B

3.9B

Sales

-215M

15B

P/E

Sector Avg

27.106

49.888

EPS

1.29

Dividend yield

1.72

Profit margin

25.602

Employees

96,100

EBITDA

1.1B

5.7B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+21.66% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.72%

2.38%

Next Earnings

27 lip 2026

Next Ex Dividend date

6 sie 2026

Market Stats

By TradingEconomics

Market Cap

-12B

279B

Previous open

13758.51

Previous close

13762

News Sentiment

By Acuity

39%

61%

118 / 344 Ranking in Healthcare

AstraZeneca PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 kwi 2026, 16:28 UTC

Earnings

Correction to AstraZeneca Update

DJ

Read

29 kwi 2026, 15:11 UTC

Earnings

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

DJ

Read

29 kwi 2026, 06:31 UTC

Earnings

AstraZeneca Gets Revenue Boost From Cancer Drugs

DJ

Read

1 cze 2026, 10:56 UTC

Market Talk
Earnings

AstraZeneca's First Data on Head and Neck Cancer Drug Looks Unexciting -- Market Talk

DJ

Read

29 maj 2026, 08:15 UTC

Market Talk
Earnings

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

DJ

Read

21 maj 2026, 11:06 UTC

Market Talk

AstraZeneca Set for Busy End of Year -- Market Talk

DJ

Read

13 maj 2026, 12:29 UTC

Market Talk

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

DJ

Read

13 maj 2026, 11:54 UTC

Market Talk

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

DJ

Read

1 maj 2026, 09:31 UTC

Market Talk

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

DJ

Read

29 kwi 2026, 10:29 UTC

Market Talk
Earnings

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

DJ

Read

29 kwi 2026, 10:06 UTC

Market Talk
Earnings

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

DJ

Read

29 kwi 2026, 09:53 UTC

Market Talk
Earnings

AstraZeneca Seems in Fine Health -- Market Talk

DJ

Read

29 kwi 2026, 06:05 UTC

Earnings

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

DJ

Read

29 kwi 2026, 06:04 UTC

Earnings

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

DJ

Read

29 kwi 2026, 06:04 UTC

Earnings

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

DJ

Read

29 kwi 2026, 06:03 UTC

Earnings

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

DJ

Read

29 kwi 2026, 06:03 UTC

Earnings

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

DJ

Read

29 kwi 2026, 06:02 UTC

Earnings

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

DJ

Read

29 kwi 2026, 06:01 UTC

Earnings

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

DJ

Read

29 kwi 2026, 06:01 UTC

Earnings

AstraZeneca Backs 2026 View

DJ

Read

29 kwi 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Adj EPS $2.58

DJ

Read

29 kwi 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Rev $15.29B

DJ

Read

29 kwi 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Pretax Pft $3.91B

DJ

Read

29 kwi 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Oper Pft $4.25B

DJ

Read

29 kwi 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Net Pft $3.08B

DJ

Read

29 kwi 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q EPS $1.97

DJ

Read

27 kwi 2026, 10:48 UTC

Market Talk

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

DJ

Read

10 kwi 2026, 11:57 UTC

Market Talk

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

DJ

Read

10 kwi 2026, 10:26 UTC

Market Talk
Earnings

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

DJ

Read

2 kwi 2026, 09:16 UTC

Market Talk

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

DJ

Read

Peer Comparison

Price change

AstraZeneca PLC Forecast

Price Target

By TipRanks

21.66% upside

12 Months Forecast

Average 16,071.15 GBX  21.66%

High 18,600 GBX

Low 11,300 GBX

Based on 15 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

13

Buy

1

Hold

1

Sell

Based on 15 analysts giving stock ratings to AstraZeneca PLC - Dist in the past 3 months.

Sentiment

By Acuity

118 / 344 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Other stocks from the sector

GSK

GlaxoSmithKline PLC

1,921

↑ +2.64%

PETS

Pets at Home Group Plc

186.7

↑ +1.25%
help-icon Live chat